Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurooncol ; 90(1): 1-7, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18607543

ABSTRACT

Despite recent advances in treatment medulloblastoma continues to remain a vexing problem. Recently increased expression of cyclin dependent kinase 6 (CDK6) was identified as an adverse prognostic marker in medulloblastoma. Genomic amplification accounts for some, but not all of the CDK6 over-expression. We hypothesized that CDK6 expression is also regulated by microRNAs in medulloblastoma. We identified putative miR sites in the CDK6 including microRNA 124a, a brain enriched microRNA. Expression of miR 124a was significantly decreased in medulloblastoma cells compared to normal adult cerebellum. Functional association between miR 124a and CDK6 in medulloblastoma was established using luciferase assays. Additionally, re-expression of miR 124a in medulloblastoma cells decreased expression of CDK6 protein. Transfection of miR 124 significantly decreases medulloblastoma cell growth but does not alter apoptosis. Furthermore, in patient samples expression of miR 124a is significantly decreased. Our data strongly indicate that CDK6 is regulated by microRNA 124 in medulloblastoma and that miR 124 modulates medulloblastoma cell growth.


Subject(s)
Brain Neoplasms/genetics , Cyclin-Dependent Kinase 6/genetics , Gene Expression Regulation, Neoplastic , Medulloblastoma/genetics , MicroRNAs/genetics , Apoptosis/physiology , Base Sequence , Blotting, Western , Brain Neoplasms/enzymology , Cell Line, Tumor , Cell Proliferation , Cyclin-Dependent Kinase 6/metabolism , Humans , Medulloblastoma/enzymology , Molecular Sequence Data , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction
2.
Neuro Oncol ; 9(2): 135-44, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17329407

ABSTRACT

Medulloblastoma is a heterogeneous pediatric brain tumor with significant therapy-related morbidity, its five-year survival rates ranging from 30% to 70%. Improvement in diagnosis and therapy requires better understanding of medulloblastoma pathology. We used whole-genome microarray analysis to identify putative tumor suppressor genes silenced by epigenetic mechanisms in medulloblastoma. This analysis yielded 714 up-regulated genes in immortalized medulloblastoma cell line D283 on treatment with histone deacetylase (HDAC) inhibitor trichostatin A (TSA). Dickkopf-1 (DKK1), a Wnt antagonist, was found to be up-regulated on HDAC inhibition. We examined DKK1 expression in primary medulloblastoma cells and patient samples by reverse transcriptase PCR and found it to be significantly down-regulated relative to normal cerebellum. Transfection of a DKK1 gene construct into D283 cell lines suppressed medulloblastoma tumor growth in colony focus assays by 60% (P < 0.001). In addition, adenoviral vector-mediated expression of DKK1 in medulloblastoma cells increased apoptosis fourfold (P < 0.001). These data reveal that inappropriate histone modifications might deregulate DKK1 expression in medulloblastoma tumorigenesis and block its tumor-suppressive activity.


Subject(s)
Cerebellar Neoplasms/genetics , Gene Expression Regulation, Neoplastic/drug effects , Genes, Tumor Suppressor , Intercellular Signaling Peptides and Proteins/genetics , Medulloblastoma/genetics , Cell Division/drug effects , Cerebellar Neoplasms/mortality , Chromatin/genetics , Colony-Forming Units Assay , Enzyme Inhibitors/pharmacology , Gene Silencing , Histone Deacetylase Inhibitors , Humans , Hydroxamic Acids/pharmacology , Medulloblastoma/mortality , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction , Survival Analysis , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...